CPD-20 and CPD-23 exhibit improved cellular and tumor accumulation, enhanced GLS inhibition, elevated ROS induction, and a better effect on eliminating cancer cells.363 Additionally, when CB-839 was combined with erlotinib in a dual therapy for mouse NSCLC xenografts, rapid tumor regression was observed in vivo. The gene discussed is GLS; the disease is neoplasm.